Humanigen (HGEN) Stock Continues In The Right Direction With COVID-19

Humanigen HGEN Stock News

Humanigen Inc (OTCMKTS: HGEN) recently caught my attention as one of the top plays in the COVID-19 space. Today, my opinion about the stock received further validation after the company announced that it would collaborate with CTI Clinical Trial and Consulting Services to move forward with a planned Phase III clinical study in COVID-19. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

HGEN Stock Looks Even Better After Phase III Coronavirus Partnership

First and foremost, Humanigen’s claim to fame in the COVID-19 space is its proprietary Humaneered anti-human-granulocyte-macraophage colony stimulating factor (GM-CSF) monoclonal antibody.

The treatment has proven to be effective in the reduction of risk and treatment of cytokine storm in cancer patients. This is overwhelmingly important because cytokine storm is a reaction experienced by COVID-19 patients that often leads to ARDS, one of the most deadly complications of the virus.

Due to the strong safety profile and evidence of potential efficacy in coronavirus patients, the company has a planned Phase III study in COVID-19 patients. If approved, the study will be a randomized, controlled, clinical trial with lenzilumab for the prevention of ARDS and/or death in hospitalized patients with pneumonia associated with coronavirus 2 infection in COVID-19.

In today’s release, HGEN said that the study will be conducted in partnershipw with CTI. CTI is a global, privately held, full-service contract research organization. CTI specializes in complex programs for critically and chronically ill patients.

In a statement, Dr. Cameron Durrant, CEO at HGEN, had the following to offer:

Humanigen has pioneered the field of GM-CSF neutralization and, unlike others, has already conducted two Phase I and two Phase II studies, including in patients with severe respiratory conditions, with excellent safety results. We have been working on prevention of cytokine storm for nearly three years. Lenzilumab has an excellent safety and tolerability profile and has not been associated with serious adverse events, including in patients who are immunosuppressed or with severe asthma. Subject to discussion and agreement with regulatory authorities, we intend to progress as quickly as possible with this study.

The above statement was followed up by Tim Schroeder, founder and CEO at CTI. Here’s what he had to say:

The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety. We are proud to have the opportunity to collaborate on such a response with the Humanigen team and to work together to develop an effective treatment solution for those hardest hit by COVID-19.

This News Is Huge

In previous posts, I’ve mentioned that Humanigen has quite a few strategic advantages here. First and foremost, the company has an asset that is likely to be effective in COVID-19 patients that has already been through various studies and maintained a strong safety profile.

Considering that few companies actually have clinic-ready candidates, HGEN is one of the clear leaders. However, today’s news only expands the company’s strategic advantages.

CTI is no beginner in the world of biotech. The company has partnered in various clinical studies, helping a large number of companies bring their products to market. Having a partner like CTI on its side only makes HGEN more attractive.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

[vc_row full_width=”stretch_row_content td-stretch-content”][vc_column][tdm_block_hero title_text=”R2V0JTIwRnJlZSUyMEFsZXJ0cw==” title_size=”tdm-title-bg” description=”Sm9pbiUyMG91ciUyMGZyZWUlMjBtYWlsaW5nJTIwbGlzdCUyMHRvJTIwcmVjZWl2ZSUyMHN0b2NrJTIwYWxlcnRzIQ==” button_text=”Join Our Mailing List Here” button_tdicon=”tdc-font-fa tdc-font-fa-chevron-right” button_url=”https://alphastocknews.us4.list-manage.com/subscribe?u=92a9c8ec6acba6727f3eff17d&id=b717e1440e” tds_button=”tds_button3″ button_size=”tdm-btn-lg” button_tdicon-1=”tdc-font-fa tdc-font-fa-search” tds_button-1=”tds_button3″ button_size-1=”tdm-btn-lg” block_width=”1200″ content_align_horizontal=”content-horiz-center” content_align_vertical=”content-vert-center” background=”eyJ0eXBlIjoiZ3JhZGllbnQiLCJjb2xvcjEiOiJyZ2JhKDIyLDExMiwxOTEsMC44NSkiLCJjb2xvcjIiOiJyZ2JhKDAsMCwwLDAuODUpIiwibWl4ZWRDb2xvcnMiOltdLCJjc3MiOiJiYWNrZ3JvdW5kOiAtd2Via2l0LWxpbmVhci1ncmFkaWVudCgwZGVnLHJnYmEoMCwwLDAsMC44NSkscmdiYSgyMiwxMTIsMTkxLDAuODUpKTtiYWNrZ3JvdW5kOiBsaW5lYXItZ3JhZGllbnQoMGRlZyxyZ2JhKDAsMCwwLDAuODUpLHJnYmEoMjIsMTEyLDE5MSwwLjg1KSk7IiwiY3NzUGFyYW1zIjoiMGRlZyxyZ2JhKDAsMCwwLDAuODUpLHJnYmEoMjIsMTEyLDE5MSwwLjg1KSJ9″][/vc_column][/vc_row]

This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Humanigen, CNA Finance has been hired for a period beginning on 3/23/20 and ending on 4/323/20 to conduct digital advertising and marketing and publicly disseminate information about HGEN via Websites and Email. We have an agreement and are currently owed $10,000 by via bank wire transfer to cover the cost of content production. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Humanigen has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.